Ischemic stroke preventive drugs according to new guidelines and investigation for stroke
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Now I have comprehensive information from multiple authoritative sources. Let me compile the full answer.
Ischemic Stroke: Preventive Drugs & Investigation
INVESTIGATIONS FOR STROKE
Immediate / Emergency Workup (All Patients)
| Investigation | Purpose |
|---|---|
| Non-contrast CT brain | First-line — excludes hemorrhagic stroke, identifies mimics; required before thrombolytics |
| MRI brain (DWI) | Superior for early ischemic changes, lacunar infarcts, posterior fossa lesions |
| Bedside glucose | Rapidly excludes hypoglycemia (most common stroke mimic) |
| ECG | Detects atrial fibrillation (most important cardioembolic cause), acute MI, and ECG abnormalities associated with stroke |
| CBC + platelet count | Detects polycythemia, thrombocytosis, thrombocytopenia |
| Coagulation studies (PT/INR, aPTT) | Rules out coagulopathy; required if thrombolytics are being considered |
| Serum electrolytes | Rules out metabolic mimics (hyponatremia, hypocalcemia) |
| Cardiac biomarkers (Troponin, BNP) | Elevated troponin predicts 3-month mortality; elevated BNP within 48 h identifies cardioembolic mechanism (OR 4.35) |
| Pulse oximetry / ABG | Detects hypoxia; give O₂ only if saturation <94% |
| Renal and liver function | Baseline before initiating anticoagulation or statins |
| Lipid profile | Guides statin therapy for secondary prevention |
| Blood glucose / HbA1c | Diabetes is a major modifiable risk factor |
Vascular Imaging
| Investigation | Indication |
|---|---|
| Carotid Doppler ultrasound | Screening for carotid stenosis (first step when bruit is found) |
| CT angiography (CTA) | Rapid assessment of large vessel occlusion and intracranial vasculature |
| MR angiography (MRA) | Non-invasive assessment of carotid and intracranial arteries |
| Digital subtraction angiography (DSA) | Gold standard for vascular anatomy when intervention is planned |
| Transcranial Doppler (TCD) | Detects emboli, evaluates intracranial stenosis |
Cardiac Workup (Source of Embolism)
| Investigation | Indication |
|---|---|
| Echocardiogram (TTE/TEE) | Detects mural thrombus, valvular disease, patent foramen ovale (PFO), cardiac wall motion abnormality |
| Prolonged cardiac monitoring (Holter, implantable loop recorder) | Detects paroxysmal atrial fibrillation — up to 30 days monitoring recommended in cryptogenic stroke |
Additional/Selective Tests
- Thrombophilia screen (protein C, S, antithrombin III, factor V Leiden, antiphospholipid antibodies) — in young patients and cryptogenic stroke
- Syphilis serology (VDRL/TPHA) — vasculitis-related stroke
- ESR, ANA, ANCA — if vasculitis is suspected
- Urine drug screen — cocaine/amphetamines in young patients
- Urine protein / renal workup — if hypertensive nephropathy
PREVENTIVE DRUGS FOR ISCHEMIC STROKE
A. Primary Prevention
1. Anticoagulants (for Atrial Fibrillation)
The pivotal indication: AF is the dominant preventable cause of cardioembolic stroke. The CHA₂DS₂-VASc score guides treatment.
| Drug | Class | Notes |
|---|---|---|
| Apixaban | Direct Xa inhibitor | Slightly fewer strokes and less cerebral hemorrhage than warfarin (ARISTOTLE trial); preferred DOAC |
| Dabigatran | Direct thrombin inhibitor | Similar stroke reduction to warfarin; reversible with idarucizumab |
| Rivaroxaban | Direct Xa inhibitor | Once-daily dosing; similar efficacy to warfarin |
| Edoxaban | Direct Xa inhibitor | Alternative DOAC |
| Warfarin | Vitamin K antagonist | Target INR 2–3; requires regular monitoring; fewer drug interactions with DOACs |
| Aspirin | Antiplatelet | Used in low-risk AF (CHA₂DS₂-VASc = 0 or "lone fibrillators" <65 years, no risk factors); inferior to anticoagulation overall |
DOACs are preferred over warfarin: no routine INR monitoring, fewer drug interactions. Reversal agents exist (idarucizumab for dabigatran; andexanet alfa for Xa inhibitors).
2. Antihypertensives
- ACE inhibitors / ARBs, calcium channel blockers, thiazide diuretics — Blood pressure control is the single most effective measure for primary stroke prevention.
3. Statins
- High-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) — Target LDL <70 mg/dL reduces first stroke risk in high-risk patients.
B. Secondary Prevention (Post-Stroke / Post-TIA)
1. Antiplatelet Agents (Non-cardioembolic stroke)
Routine antiplatelet therapy is recommended unless there is a specific indication for anticoagulation (e.g., AF, prosthetic valve).
| Drug | Dose | Notes |
|---|---|---|
| Aspirin | 50–325 mg daily | First-line; established benefit (IST, CAST trials) |
| Clopidogrel | 75 mg daily | Alternative or combined with aspirin short-term |
| Ticagrelor | 90 mg twice daily (180 mg load) | No better than aspirin alone at 90 days as monotherapy |
| Aspirin + dipyridamole SR | 25/200 mg twice daily | Effective combination option |
| Aspirin + clopidogrel (dual antiplatelet — DAPT) | Short-term (21 days) | Preferred in minor stroke/high-risk TIA (ABCD2 score); CHANCE trial: reduces 90-day recurrence without increasing hemorrhage; POINT trial confirms benefit but more systemic bleeding with 90 days. Long-term DAPT increases serious bleeding — not recommended |
2. Anticoagulants (Cardioembolic Stroke)
- DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) — Preferred for AF-related stroke secondary prevention over warfarin
- Warfarin — Still used for prosthetic heart valves and some special indications
- Timing: Begin anticoagulation once patient is stabilized, generally ≥24 hours after acute ischemic stroke (risk of hemorrhagic transformation in large infarcts must be weighed)
3. Statins (High-Intensity)
- Atorvastatin 40–80 mg or Rosuvastatin 20–40 mg — Target LDL <70 mg/dL reduces recurrent stroke and major cardiovascular events by ~20% (SPARCL trial: 2% absolute risk reduction over 5 years with high-dose statin).
- PCSK9 inhibitors (evolocumab, alirocumab) — Alternative if statins contraindicated or LDL targets not reached.
- Stopping statin after acute ischemic stroke is associated with increased morbidity and mortality.
4. Antihypertensives
- Recommended after stabilization (≥24 hours post-stroke)
- Target: systolic BP <130 mmHg (especially for lacunar infarctions — reduces intracerebral hemorrhage risk)
- A 10/5 mmHg reduction → ~25% reduction in recurrent stroke risk
- Preferred agents: diuretics, CCBs, ACE inhibitors, ARBs
5. Insulin Sensitizers
- Pioglitazone — In patients with ischemic stroke/TIA + insulin resistance (but not diabetes), reduces risk of subsequent stroke or MI (PROactive-related data).
C. Carotid Revascularization (Procedural Prevention)
| Stenosis | Recommendation |
|---|---|
| Symptomatic 70–99% | Carotid endarterectomy (CEA) reduces risk by ~50% |
| Symptomatic 50–69% | CEA offers ~16% relative risk reduction |
| Symptomatic <50% | No benefit from revascularization |
| Asymptomatic >70% | Benefit uncertain in era of aggressive medical therapy; trials ongoing |
Summary: Drug Classes at a Glance
| Goal | Drug(s) |
|---|---|
| AF — Primary/Secondary prevention | DOACs (apixaban preferred), warfarin |
| Non-cardioembolic stroke — Secondary | Aspirin, clopidogrel, aspirin+dipyridamole |
| High-risk TIA/minor stroke | Short-term DAPT (aspirin + clopidogrel, 21 days) |
| Cholesterol lowering | High-intensity statin; PCSK9 inhibitors |
| BP control | ACE-I / ARB / CCB / thiazide |
| Insulin resistance (post-stroke) | Pioglitazone |
Sources: Adams and Victor's Principles of Neurology (12th ed.) — pp. 824–829; Goldman-Cecil Medicine — pp. 3944–3946; Tintinalli's Emergency Medicine — p. 1168
This is a shared conversation. Sign in to Orris to start your own chat.